The company is aiming to become the first to offer chronic pain sufferers a patch that provides sustained-release oxycodone into the bloodstream.
Dr Esra Ogru, executive vice president of R&D, said: “Developing its pain relief pipeline will build on the success of previous transdermal clinical trials and provide a platform for the development of many other products.”
Dr Ogru added: “With this trial, we will be using our transdermal technology to deliver oxycodone in a sustained-release formulation with the aim of treating chronic pain. Currently oxycodone is not available in a transdermal route of administration.”